Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
45 hedge funds and large institutions have $269M invested in Talis Biomedical Corporation Common Stock in 2021 Q1 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$126M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$99.8M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$25.8M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$18.3M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.1M |
Top Sellers
TLIS Hedge Fund Activity: Q1 2021 in Review
45 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q1 2021, worth a combined $269M.
Buyers outnumbered sellers: 45 funds opened new TLIS positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $126M.
- 45 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $269M of Talis Biomedical Corporation Common Stock stock for Q1 2021.
- 45 funds opened new Talis Biomedical Corporation Common Stock positions in Q1 2021 and 0 closed out, a net change of +45 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q1 2021 was Baker Bros. Advisors, an estimated $126M added.
Based on aggregated 13F filings for Q1 2021.